Burkitt-like post-transplant lymphoproliferative disorder (PTLD) presenting with breast mass in a renal transplant recipient: a report of a rare case

Law, Man Fai; Chan, Hay Nun; Leung, Charlotte; Lai, Ho Kei; Ha, Chung Yin; Ng, Chi‐Fai; Yeung, Yiu Ming; Yip, Sze Fai

doi:10.1007/s00277-014-2094-0

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20,22,24 Less commonly used chemotherapy regimens for malignant T-Cell PTLD include separate courses of cyclophosphamide, vincristine, doxorubicin, and dexamethasone, followed by methotrexate and cytarabine (HyperCVAD) or the use of etoposide, prednisone, vincristine, cyclophosphamide, and hydroxydaunorubicin (EPOCH) chemotherapy. 38,39 Given the wide range of characteristics of PTLD and treatment regimens presented here, it is suggestive that investigation of specific PTLD characteristics will be beneficial. With relatively higher incidence rates higher than other solid organ transplants, studies assessing survival after PTLD onset in lung transplant recipients appear warranted.…”

mentioning

confidence: 94%

“…Further treatment of malignant PTLD includes the use of chemotherapy agents with steroids, cyclophosphamide, doxorubicin or daunorubicin, vincristine, prednisone (CHOP), with the addition of rituximab for CD20 + PTLD (R‐CHOP), which has reported to achieve complete remission in 40%‐60% of patients . Less commonly used chemotherapy regimens for malignant T‐Cell PTLD include separate courses of cyclophosphamide, vincristine, doxorubicin, and dexamethasone, followed by methotrexate and cytarabine (HyperCVAD) or the use of etoposide, prednisone, vincristine, cyclophosphamide, and hydroxydaunorubicin (EPOCH) chemotherapy …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review and meta‐analysis of post‐transplant lymphoproliferative disorder in lung transplant recipients

Cheng

Moore

Iasella

et al. 2018

Clinical Transplantation

View full text Add to dashboard Cite

A systematic review of papers in English on post-transplant lymphoproliferative disorder (PTLD) in lung transplant recipients (LTR) using MEDLINE, EMBASE, SCOPUS, and Cochrane databases was performed. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations were strictly adhered to. Pooled odds ratios (pOR) were calculated from a random-effects model, and heterogeneity among studies was quantitated using I values. Fourteen studies published from 2005 to 2015 were included in the meta-analysis. One hundred and sixty-four lung transplant recipients were included. LTRs who received single vs bilateral were associated with a 7.67-fold risk of death after PTLD (6 studies with 64 LTRs; pOR 7.67 95% CI 1.98-29.70; P = .003). pOR of death for early onset PTLD (<1 year post-LT) vs late onset (>1 year post-LT) was not different (3 studies with 72 LTRS; pOR 0.62, 95% CI 0.20-1.86, P = .39). Standardized mean difference (SMD) in time from transplant to PTLD onset between LTRs who died vs alive was not different (9 studies with 109 LTRs; SMD 0.03, 95% CI -0.48-0.53, P = .92). Survival in polymorphic vs monomorphic PTLD and extranodal vs nodal disease was similar (4 studies with 31 LTRs; pOR 0.44, 95% CI 0.08-2.51; P = .36. 6 studies with 81 LTRs; pOR 1.05 95% CI 0.31-3.52, P = .94). This meta-analysis demonstrates that single LTRs are at a higher risk of death vs bilateral LTRs after the development of PTLD.

show abstract

mentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Systematic review and meta‐analysis of post‐transplant lymphoproliferative disorder in lung transplant recipients

Cheng

Moore

Iasella

et al. 2018

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

Posttransplant monomorphic Burkitt’s lymphoma: clinical characteristics and outcome of a multicenter series

Bobillo¹,

Sánchez‐González

Giné

et al. 2018

Ann Hematol

View full text Add to dashboard Cite

Burkitt's monomorphic posttransplant lymphoproliferative disorder (B-PTLD) is an uncommon subtype of PTLD. Owing to the paucity of this complication, clinical characteristics and outcome has not been fully described. Clinical characteristics and outcomes of 20 patients diagnosed with B-PTLD from 10 transplant centers belonging to the GEL/TAMO group were reviewed. Median time from transplant to B-PTLD was 7.2 years. All the cases fulfill the morphologic and genetic criteria of B-PTLD, whereas Epstein-Barr virus (EBV) was detected in 70% of cases. Patients were treated with different chemotherapy combinations, and three patients received upfront rituximab monotherapy. The great majority of patients receiving CHOP-like regimens attained a complete response (CR) (73%), similar to that obtained with dose-intensive chemotherapy (83% CR). In contrast, patients receiving upfront rituximab monotherapy required subsequent chemotherapy. Two patients (10%) died during treatment due to infection. The median progression-free survival and overall survival (OS) were 16 months and 139 months, respectively. When analyzing variables predicting for OS, we found that patients with bone marrow involvement had an adverse prognosis, with a median OS of 6 months (p = 0.008). In conclusion, B-PTLD is an uncommon complication usually associated with EBV infection and with an aggressive clinical course, particularly in patients with bone marrow involvement. High-dose chemoimmunotherapy obtained similar responses to R-CHOP, suggesting that R-CHOP could be an adequate alternative for these patients. In contrast, rituximab monotherapy does not seem to be effective enough to control the disease.

show abstract

Post-transplant Lymphoproliferative Disorder Presenting as Breast Nodule and Intestinal Obstruction in a Renal Transplant Recipient: A Case Report

Goel

Gupta

et al. 2022

Transplantation Proceedings

View full text Add to dashboard Cite

Burkitt-like post-transplant lymphoproliferative disorder (PTLD) presenting with breast mass in a renal transplant recipient: a report of a rare case

Cited by 4 publications

References 9 publications

Systematic review and meta‐analysis of post‐transplant lymphoproliferative disorder in lung transplant recipients

Systematic review and meta‐analysis of post‐transplant lymphoproliferative disorder in lung transplant recipients

Posttransplant monomorphic Burkitt’s lymphoma: clinical characteristics and outcome of a multicenter series

Post-transplant Lymphoproliferative Disorder Presenting as Breast Nodule and Intestinal Obstruction in a Renal Transplant Recipient: A Case Report

Contact Info

Product

Resources

About